The merger is essentially a reverse takeover where Werewolf's public shell is acquired by Ambros. Werewolf's current stockholders will be diluted to approximately 6.4% ownership. The merger is contingent on stockholder approval, Nasdaq listing, and minimum PIPE proceeds of $100 million. Monitor stockholder vote and Nasdaq listing approval. If the merger fails, Werewolf faces likely dissolution or liquidation with potentially no value for common stockholders.
Price Chart
Executive Summary
Werewolf Therapeutics filed an S-4/A registration statement for a reverse merger with Ambros Therapeutics, where Ambros will become a wholly owned subsidiary of Werewolf and Werewolf will be renamed Ambros Therapeutics. The merger values Ambros at $500 million and Werewolf at $47.5 million, with a concurrent $150 million PIPE financing. Pre-merger Werewolf equity holders (excluding PIPE investors) are expected to own approximately 6.4% of the combined company, while Ambros holders will own approximately 72.0% and PIPE investors 21.6%. The filing also discloses that Werewolf sold its preclinical INDUCER platform and certain INDUKINE platform assets (excluding WTX-124 and WTX-330) to EMD Serono for $33 million total consideration ($28 million upfront plus $5 million upon tech transfer completion), and entered into a license back agreement for patents needed to continue its WTX-124 and WTX-330 programs and fulfill obligations to Jazz and Harpoon.
Key Facts
- Werewolf entered into a merger agreement with Ambros Therapeutics on August 21, 2026, with Ambros valued at $500 million and Werewolf at $47.5 million.
- A concurrent PIPE financing of $150 million is a condition to the merger, with a minimum of $100 million required.
- Pre-merger Werewolf equity holders (excluding PIPE investors) will own approximately 6.4% of the combined company; Ambros holders ~72.0%; PIPE investors ~21.6%.
- Werewolf sold its preclinical INDUCER platform and certain INDUKINE platform assets (excluding WTX-124 and WTX-330) to EMD Serono for $33 million total ($28 million upfront + $5 million tech transfer payment).
- Werewolf entered into a license back agreement with EMD Serono for patents needed to continue WTX-124 and WTX-330 development and fulfill obligations to Jazz and Harpoon.
- Werewolf has substantial doubt about its ability to continue as a going concern; as of June 30, 2026, it had $22.0 million cash and an accumulated deficit of $485.3 million.
- Werewolf received a Nasdaq deficiency notice for failing to meet the minimum bid price requirement and has until February 1, 2027 to regain compliance.
- The combined company's common stock is expected to trade on Nasdaq under the symbol AMBX, contingent on Nasdaq approval.
- Werewolf stockholders will receive one CVR per share for potential proceeds from future monetization of WTX-124 and WTX-330 assets.
- Ambros' lead product candidate is neridronate, currently in a Phase 3 trial for CRPS-1; Ambros had a net loss of $19.9 million for the six months ended June 30, 2026.
Financial Impact
Werewolf's existing stockholders face massive dilution, retaining only ~6.4% of the combined company. The $150 million PIPE provides capital but at the cost of 21.6% ownership to new investors. Werewolf's cash position of $22 million is insufficient to continue operations without the merger. The EMD asset sale provided $28 million upfront with an additional $5 million contingent payment.
Risk Factors
- Massive dilution: existing Werewolf stockholders will own only ~6.4% of the combined company.
- Merger failure risk: if conditions are not met, Werewolf may need to dissolve or liquidate, potentially leaving stockholders with no value.
- Nasdaq delisting risk: Werewolf has not regained compliance with the minimum bid price requirement.
- Going concern risk: Werewolf has substantial doubt about its ability to continue as a going concern without the merger.
- CVRs may pay nothing: the CVRs for WTX-124 and WTX-330 proceeds are contingent and may result in no payment.
- Ambros' neridronate program faces clinical and regulatory risks, including prior failed Phase 3 trials by Grnenthal.
Market Snapshot
Investment Themes
Documents Analyzed
This report is based on 3 SEC documents filed with EDGAR.
| Document | Accession Number |
|---|---|
| S-4/A Filing (Primary) | 0001140361-26-040784 |
| Document: ny20081588x2_ex10-54.htm | 0001140361-26-040784 |
| Document: ny20081588x2_ex10-55.htm | 0001140361-26-040784 |
Filters
| Type | Now | ||||
|---|---|---|---|---|---|
Oct 26, 2026 1d ago | S-4/A | $0.9806 | awaiting T+5 | — | $0.9810 (−0.04%) |
Sep 22, 2026 5w ago | S-4 | $0.9894 $0.9223 | ▲ +6.78% | ▲ +6.11% | $0.9810 (+0.85%) |
Sep 21, 2026 5w ago | SC 13G | $0.9800 $0.9300 | ▼ −5.10% | ▼ −4.08% | $0.9810 (+0.10%) |
Aug 21, 2026 9w ago | 425 | $0.8740 $0.9433 | ▲ +7.93% | ▲ +7.46% | $0.9810 (+12.24%) |
Aug 21, 2026 9w ago | 8-K | $0.8740 $0.9433 | ▲ +7.93% | ▲ +7.46% | $0.9810 (+12.24%) |
Aug 21, 2026 9w ago | Press Release | $0.8740 $0.9433 | ▼ −7.93% | ▼ −7.46% | $0.9810 (−12.24%) |
Jul 31, 2026 12w ago | 8-K | $0.3531 $0.3971 | ▲ +12.46% | ▲ +8.95% | $0.9810 (+177.82%) |
Jul 31, 2026 12w ago | Press Release | $0.3531 $0.3971 | ▲ +12.46% | ▲ +8.95% | $0.9810 (+177.82%) |
Jun 29, 2026 17w ago | 144 | $0.3599 $0.3200 | ▲ +11.09% | ▲ +11.69% | $0.9810 (−172.58%) |
Jun 29, 2026 17w ago | 144 | $0.3599 $0.3200 | ▲ +11.09% | ▲ +11.69% | $0.9810 (−172.58%) |
US Market Status
Subscribe to SecBot
Get Real-Time SEC Filing Intelligence
Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.
Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers